SCHEMBL4718544

SCHEMBL4718544

Fc1ccc(F)c(-c2cc(Nc3cccc4cnccc34)ncn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
THRB P10828 1/20 0.42
HTT P42858 1/20 0.42
BLM P54132 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 1/20 0.41
KDR P35968 2/20 0.40
TRPV1 Q8NER1 2/20 0.39
P2RX7 Q99572 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP19A1 P11511 2/20 0.38
CYP11B1 P15538 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715734 0.84 TRPV1 (0.45) ALDH1A1MAPTMEN1THRBHTT
SCHEMBL4716399 0.83 KDR (0.47) ALDH1A1KDRTRPV1CYP1A2CYP2D6
SCHEMBL4716859 0.80 TRPV1 (0.42) ALDH1A1MAPTMEN1THRBHTT
SCHEMBL4717963 0.80 IKBKE (0.44) ALDH1A1MAPTMEN1BLMKMT2A
SCHEMBL4716052 0.79 PDE4B (0.51) ALDH1A1MAPTMEN1HTTBLM
SCHEMBL4716401 0.79 TRPV1 (0.48) ALDH1A1MAPTHTTBLMKDM4E
SCHEMBL4717106 0.79 TRPV1 (0.43) ALDH1A1MAPTMEN1HTTBLM
SCHEMBL4718729 0.77 CCR4 (0.43) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL4718692 0.77 TRPV1 (0.49) ALDH1A1MAPTKDM4EKDRTRPV1
SCHEMBL4718782 0.77 TRPV1 (0.50) ALDH1A1MAPTKDM4ETRPV1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 TGFBR1 762/4885ALDH1A1 2473/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.